OR WAIT null SECS
December 31, 2024
Article
To celebrate the close of 2024, we're recapping the 10 most popular approval articles across the HCPLive Network of brands.
December 26, 2024
We spotlight 5 impactful regulatory decisions scheduled to occur during the first quarter of 2025.
This listicle highlights 5 major approvals and 5 trial updates in cardiovascular care from 2024.
December 24, 2024
Video
To celebrate the close of 2024, we surveyed top cardiologist on what they view as the biggest storyline in their field from the past year.
December 23, 2024
A study indicates that dyslipidemia may be associated with a greater risk of psoriasis development.
December 05, 2024
Greg Duck, PA-C shared insights from his CAPP 2024 presentation on tailoring medical management and effective treatment of methamphetamine-induced cardiomyopathy.
December 01, 2024
Our Cardiology Month in Review for November 2024 spotlights the approval of acoramidis and top content from AHA 2024.
November 26, 2024
The FDA set the Prescription Drug User Fee Act (PDUFA) date for the investigational RNAi therapeutic as March 23, 2025.
November 23, 2024
With approval, acoramaidis becomes the first agent with a label specifying near-complete stabilization of TTR.
November 21, 2024
Milind Desai, MD describes favorable real-world safety outcomes from mavacamten use over 22 months of the Risk Evaluation and Mitigation Strategy (REMS) program.
